Home > Insider Trading > Filing (0000919574-18-003087)

Filing Details

Accession Number:: 0000919574-18-003087
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-04-17 21:59:59
Reporting Period:: 2018-04-13

Accepted Time:: 2018-04-17 21:59:59
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1372514	Eyegate Pharmaceuticals Inc	EYEG	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1601086	Armistice Capital, Llc	510 Madison Avenue, 22Nd Floor New York NY 10022	No	No	Yes	No
1633584	Ltd. Fund Master Capital Armistice	510 Madison Avenue, 22Nd Floor New York NY 10022	No	No	Yes	No
1706140	Steven Boyd	510 Madison Avenue, 22Nd Floor New York NY 10022	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-04-13	7,425,193	$0.33	10,657,723	No	4	P	Direct
Common Stock	Acquisiton	2018-04-13	0	$0.00	10,657,723	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2018-04-13	0	$0.00	10,657,723	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2018-04-16	1,159,167	$0.38	11,816,890	No	4	P	Direct
Common Stock	Acquisiton	2018-04-16	0	$0.00	11,816,890	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2018-04-16	0	$0.00	11,816,890	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2018-04-17	1,895,610	$0.44	13,712,500	No	4	P	Direct
Common Stock	Acquisiton	2018-04-17	0	$0.00	13,712,500	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2018-04-17	0	$0.00	13,712,500	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Direct
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Direct
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrants	Acquisiton	2018-04-16	5,468,750	$0.21	5,468,750	$0.32
Common Stock	Warrants	Acquisiton	2018-04-16	0	$0.00	0	$0.32
Common Stock	Warrants	Acquisiton	2018-04-16	0	$0.00	0	$0.32

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
5,468,750	2018-04-17	2023-04-17	No	4	P	Direct
5,468,750	2018-04-17	2023-04-17	No	4	P	Indirect
5,468,750	2018-04-17	2023-04-17	No	4	P	Indirect

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Warrants	$1.50	2017-06-14	2022-06-14	2,000,000	2,000,000	Indirect
Common Stock	Warrants	$1.50	2017-06-14	2022-06-14	0	2,000,000	Indirect
Common Stock	Warrants	$1.50	2017-06-14	2022-06-14	0	2,000,000	Indirect
Common Stock	Warrants	$0.32	2018-04-17	2023-04-17	15,937,500	15,937,500	Direct
Common Stock	Warrant	$0.32	2018-04-17	2023-04-17	0	15,937,500	Indirect
Common Stock	Warrant	$0.32	2018-04-17	2023-04-17	0	15,937,500	Indirect

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2022-06-14	2,000,000	2,000,000	Indirect
2022-06-14	0	2,000,000	Indirect
2022-06-14	0	2,000,000	Indirect
2023-04-17	15,937,500	15,937,500	Direct
2023-04-17	0	15,937,500	Indirect
2023-04-17	0	15,937,500	Indirect

Footnotes

This constitutes the weighted average purchase price. The prices range from $0.30 to $0.351. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
The reported securities are directly owned by Armistice Capital Master Fund, Ltd.
The reported securities are directly owned by Armistice Capital Master Fund, Ltd., a Cayman Islands corporation, and may be deemed to be indirectly beneficially owned by Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund, Ltd. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital, LLC and Director of Armistice Capital Master Fund, Ltd.
This constitutes the weighted average purchase price. The prices range from $0.329 to $0.395. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
This constitutes the weighted average purchase price. The prices range from $0.393 to $0.492. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
These warrants are currently exercisable, subject to a blocker provision that prevents Armistice Capital Master Fund, Ltd.from exercising the warrants if it would be more than a 9.99% beneficial owner of the Common Shares following such exercise.
These warrants are currently excercisable, subject to a blocker provision that prevents Armistice Capital Master Fund, Ltd.from exercising the warrants if it would be more than a 4.99% beneficial owner of the Common Shares following such exercise.
The Series C Convertible Preferred Stock has no expiration date and is convertible at any time at the option of Armistice Capital Master Fund, Ltd., subject to a blocker provision that prevents Armistice Capital Master Fund, Ltd.from converting the Series C Convertible Preferred Stock into Common Shares if it would be more than a 4.99% beneficial owner of the Common Shares following such conversion.